SYH2069
/ CSPC Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
December 05, 2025
GLP-1/GIP receptor dual-biased agonist polypeptide injection (SYH2069 injection) obtains clinical trial approval in the U.S.
(CSPC Press Release)
IND • Obesity
1 to 1
Of
1
Go to page
1